Jasper Therapeutics (NASDAQ:JSPR) Cut to “Sell” at Wall Street Zen

Wall Street Zen lowered shares of Jasper Therapeutics (NASDAQ:JSPR) from a hold rating to a sell rating in a research report released on Saturday morning,Wall Street Zen reports.

JSPR has been the subject of several other reports. HC Wainwright reaffirmed a “buy” rating on shares of Jasper Therapeutics in a research note on Tuesday, August 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Friday, July 17th. Finally, Piper Sandler started coverage on shares of Jasper Therapeutics in a report on Wednesday, August 12th. They issued an “overweight” rating and a $2.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $7.33.

Jasper Therapeutics Trading Down 2.4%

NASDAQ:JSPR opened at $0.60 on Friday. Jasper Therapeutics has a 12 month low of $0.32 and a 12 month high of $2.69. The business’s 50-day moving average is $0.71 and its 200 day moving average is $0.78. The company has a market capitalization of $20.06 million, a P/E ratio of -0.38 and a beta of 3.04.

Jasper Therapeutics (NASDAQ:JSPR) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.17. On average, research analysts forecast that Jasper Therapeutics will post -1.14 earnings per share for the current year.

About Jasper Therapeutics

Jasper Therapeutics, Inc is a clinical-stage biotechnology company developing antibody therapies for diseases driven by mast cells and for conditions requiring the controlled depletion of blood-forming stem cells. The company’s research is centered on targeting c-Kit, a receptor involved in the survival and development of mast cells and hematopoietic stem and progenitor cells.

Jasper’s lead product candidate is briquilimab, formerly known as JSP191, an investigational monoclonal antibody designed to block c-Kit activity.